#120073
Re: Farmas USA
CORONAVIRUS WATHC LIST
BCRX $ 3.00 +0.255 + (+ 9.29%)
Galidesivir
This nucleoside RNA polymerase inhibitor disrupts the viral replication process and has the potential to fight multiple viral threats at once.
BioCryst is developing galidesivir in collaboration with U.S. Government Agencies and other institutions. In September 2013, the National Institute of Allergy and Infectious Diseases (NIAID) contracted with BioCryst for the development of galidesivir as a treatment for Marburg virus disease and potentially for other filoviruses, including Ebola virus. The total funding from NIAID could be up to $39.5 million if all contract options are exercised.
https://www.biocryst.com/our-program/galidesivir/
--
Precisous I- HCH, con MACD cruzando a bullish en grafico diario
--
Precisous I- HCH, con MACD cruzando a bullish en grafico diario